Notch signaling pathway is a highly conserved cell signaling system present in most multicellular organisms. Notch is present in all metazoans, and mammals possess four different notch receptors, referred to as Notch1, Notch2, Notch3, and Notch4. The notch receptor is a single-pass transmembrane receptor protein. It is a hetero-oligomer composed of a large extracellular portion, which associates in a calcium-dependent, non-covalent interaction with a smaller piece of the notch protein composed of a short extracellular region, a single transmembrane-pass, and a small intracellular region.

Notch signaling promotes proliferative signaling during neurogenesis, and its activity is inhibited by Numb to promote neural differentiation. The notch signaling pathway is important for cell-cell communication, which involves gene regulation mechanisms that control multiple cell differentiation processes during embryonic and adult life.
### Notch Inhibitors & Modulators

#### BMS-708163
**Cat. No.: HY-50845**

**Bioactivity:** BMS-708163 is a potent inhibitor of γ-secretase, with IC\(_{50}\) of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; BMS-708163 also inhibits NICD (Notch Intracellular Domain) with IC\(_{50}\) of 0.84 nM and shows weak inhibition of CYP2C...

**Purity:** 99.93%
**Clinical Data:** Phase 2
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

#### Crenigacestat
**Cat. No.: HY-12449**

**Bioactivity:** LY3039478 is a novel and potent Notch inhibitor. In a xenograft tumor model, LY3039478 inhibit N1ICD cleavage and expression of Notch-regulated genes in the tumor microenvironment. LY3039478 is being investigated in Phase I.

**Purity:** 98.01%
**Clinical Data:** Phase 2
**Size:** 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

#### IMR-1
**Cat. No.: HY-100431**

**Bioactivity:** IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC\(_{50}\) of 6 μmol/L.

**Purity:** 99.13%
**Clinical Data:** No Development Reported
**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

#### LY-411575
**Cat. No.: HY-50752**

**Bioactivity:** LY-411575 is a potent γ-secretase inhibitor with IC\(_{50}\) of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with IC\(_{50}\) of 0.39 nM.

**Purity:** 98.71%
**Clinical Data:** No Development Reported
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

#### RO4929097
**Cat. No.: HY-11102**

**Bioactivity:** RO4929097 is a γ-secretase inhibitor with IC\(_{50}\) of 4 nM, inhibiting cellular processing of Aβ40 and Notch with IC\(_{50}\) of 14 nM and 5 nM, respectively.

**Purity:** 98.02%
**Clinical Data:** Phase 2
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

#### BMS-983970
**Cat. No.: HY-12419**

**Bioactivity:** BMS-983970 is an oral pan-Notch inhibitor for the treatment of cancer.

**Purity:** 99.21%
**Clinical Data:** No Development Reported
**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

#### FLI-06
**Cat. No.: HY-15860**

**Bioactivity:** FLI-06 is an inhibitor of Notch signaling with an EC\(_{50}\) of 2.3 μM.

**Purity:** 99.87%
**Clinical Data:** No Development Reported
**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

#### IMR-1A
**Cat. No.: HY-100431A**

**Bioactivity:** IMR-1A is the metabolite of IMR-1. IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC\(_{50}\) of 6 μmol/L.

**Purity:** 98.06%
**Clinical Data:** No Development Reported
**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

#### Psoralidin
**Cat. No.: HY-N0232**

**Bioactivity:** Psoralidin, a natural furanocoumarin, is isolated from Psoralea corylifolia L. possessing anti-cancer properties. IC\(_{50}\) value: Target: Anticancer natural compound in vitro: PSO dramatically decreased the cell viabilities in dose- and time-dependent manner. Autophagy inhibitor 3-MA blocked the...

**Purity:** 98.13%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg

#### Semagacestat
**Cat. No.: HY-10009**

**Bioactivity:** Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC\(_{50}\) of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC\(_{50}\) of 14.1 nM.

**Purity:** 98.83%
**Clinical Data:** Phase 3
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
| **Tangeretin**  
| (Tangeritin; NSC53909; NSC618905; Ponkanetin)  
| **Cat. No.:** HY-N0133 |
| **Bioactivity:** Tangeretin, a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models, and was also selected as a Notch-1 inhibitor. |
| **Purity:** 98.10% |
| **Clinical Data:** No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **tCFA15**  
| **Cat. No.:** HY-104031 |
| **Bioactivity:** tCFA15 is a trimethyl cyclohexenonic long chain fatty alcohol containing 15 carbon atoms on the side chain, promotes the differentiation of neurons, and may regulate Notch signaling. |
| **Purity:** >98% |
| **Clinical Data:** No Development Reported |
| **Size:** 250 mg, 500 mg |

| **YO-01027**  
| (Dibenzazepine; DBZ)  
| **Cat. No.:** HY-13526 |
| **Bioactivity:** YO-01027 (Dibenzazepine; DBZ) is a potent γ-secretase inhibitor with IC50 values of 2.92±0.22 and 2.64±0.30 nM for Notch and APPL cleavage, respectively. |
| **Purity:** 99.23% |
| **Clinical Data:** No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg |

| **Z-Ile-Leu-aldehyde**  
| (Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII)  
| **Cat. No.:** HY-12465 |
| **Bioactivity:** Z-Ile-Leu-aldehyde (Z-IL-CHO; GSI-XII) is a potent gamma-Secretase inhibitor, Notch signaling inhibitor. |
| **Purity:** 98.10% |
| **Clinical Data:** No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg |